Physician profile
Mark Jeffrey Abrams
NPI 1508827825
$2,796.00
in general payments reported to CMS, 2019-2025
18 companies · $948 in 2025
The $948 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $15.78 · 2021: $307 · 2022: $316 · 2023: $477 · 2024: $328 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $743.10 | 2021-2025 | |
| Abbvie INC. | $461.03 | 2023-2025 | Qulipta, Ubrelvy |
| Optinose US, INC. | $346.89 | 2019-2025 | |
| Aerin Medical INC. | $319.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $249.44 | 2022-2025 | Dupixent |
| Pfizer INC. | $181.77 | 2023-2025 | |
| Neurent Medical Limited | $139.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2019 | |
| Resmed Corp | $35.48 | 2019 | |
| Axsome Therapeutics, INC. | $32.63 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $27.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.42 | 2022 | |
| Merck Sharp & Dohme LLC | $26.68 | 2025 | Keytruda |
| Intersect Ent, INC. | $19.16 | 2021 | |
| Cook Medical LLC | $15.73 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $15.46 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $14.94 | 2024 | Ryaltris |
| Glaxosmithkline, LLC. | $14.40 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.